June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?
May 4, 2025, 10:21

Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?

Piet Ost, Radiation Oncologist at Iridium Network Antwerp, shared a post on X:

POSTCARD trial by Dr Supiot: Can durvalumab and SBRT improve outcomes in oligorecurrent Prostate Cancer?

  • No PFS benefit at 2 years vs SBRT alone.
  • Deeper PSA responses in some patients.
  • CTC count <5 linked to better outcomes.”

Piet Ost: Can Durvalumab and SBRT improve outcomes in Oligorecurrent Prostate Cancer?

More posts featuring Piet Ost.